<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30143463</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>10</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1769-6658</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>22</Volume>                    <Issue>6-7</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique</Title>                <ISOAbbreviation>Cancer Radiother</ISOAbbreviation>            </Journal>            <ArticleTitle>[Hypofractionated radiotherapy for breast cancer in elderly patients: current evidence and future perspectives].</ArticleTitle>            <Pagination>                <MedlinePgn>635-639</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S1278-3218(18)30282-8</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canrad.2018.07.127</ELocationID>            <Abstract>                <AbstractText>Adjuvant radiotherapy is the pillar of breast conserving surgery. Its omission is related with a higher risk of local recurrence and of breast cancer related or non-related mortality. It is of paramount importance to guarantee this treatment is fully administered to all patients after breast conserving surgery, including the elderly. In the last three decades several hypofractionated treatment schemes have shown their non-inferiority, allowing for treatment time reduction facilitating adhesion to treatment and reducing radiotherapy burden. This review focuses on the schemes and indications which have been validated by large phase 3 trials and those which are still under evaluation.</AbstractText>                <CopyrightInformation>Copyright © 2018 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Rivin Del Campo</LastName>                    <ForeName>E</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Service d'oncologie radiothérapie, hôpitaux universitaires Est Parisien, hôpital Tenonn, AP-HP, 4, rue de la Chine, 75020 Paris, France; Université Paris Sorbonne, 75020 Paris, France. Electronic address: eleonorrivin@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rivera</LastName>                    <ForeName>S</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Département de radiothérapie, Gustave-Roussy cancer campus, 114, rue Édouard-Vaillant, 94800 Villejuif, France; Université Paris-Sud, 91405 Orsay cedex, France.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>fre</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <VernacularTitle>Radiothérapie hypofractionnée des cancers du sein chez la femme âgée : état des lieux et perspectives.</VernacularTitle>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>22</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>France</Country>            <MedlineTA>Cancer Radiother</MedlineTA>            <NlmUniqueID>9711272</NlmUniqueID>            <ISSNLinking>1278-3218</ISSNLinking>        </MedlineJournalInfo>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>                <QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName>                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000069473" MajorTopicYN="Y">Dose Hypofractionation</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005544" MajorTopicYN="N">Forecasting</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008408" MajorTopicYN="N">Mastectomy</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Cancer du sein</Keyword>            <Keyword MajorTopicYN="N">Elderly</Keyword>            <Keyword MajorTopicYN="N">Hypofractionation</Keyword>            <Keyword MajorTopicYN="N">Hypofractionnement</Keyword>            <Keyword MajorTopicYN="N">Radiotherapy</Keyword>            <Keyword MajorTopicYN="N">Radiothérapie</Keyword>            <Keyword MajorTopicYN="N">Sujet âgé</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>10</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>14</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30143463</ArticleId>            <ArticleId IdType="pii">S1278-3218(18)30282-8</ArticleId>            <ArticleId IdType="doi">10.1016/j.canrad.2018.07.127</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>